StreetInsider.com News Articles

Form 4 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260827/26991651.html

Form 4 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260827/26991651.html

Form 3 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991648.html

Form 3 REGENXBIO Inc. For: Aug 25 Filed by: Ciongoli Gregory Austin

Thu, 27 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260827/26991648.html

Regenxbio Inc. (RGNX) PT Lowered to $21 at H.C. Wainwright

Wed, 26 Aug 2026 06:44:49 -0400

(Updated - August 26, 2026 6:44 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $21.00 (from $23.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, REGENXBIO announced that the FDA had placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE study. The findings were identified through an expanded MRI monitoring plan, implemented by the company a few months ago following the clinical hold related to RGX-111. The five participants received intracisternal or intraventricular RGX-121 approximately three to six years ago. Investigators

Regenxbio Inc. (RGNX) PT Lowered to $21 at H.C. Wainwright

Wed, 26 Aug 2026 06:44:49 -0400

(Updated - August 26, 2026 6:44 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $21.00 (from $23.00) while maintaining a Buy rating.

Form 8-K REGENXBIO Inc. For: Aug 25

Tue, 25 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260825/26975511.html

Form 8-K REGENXBIO Inc. For: Aug 25

Tue, 25 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260825/26975511.html

RegenxBio adds new board member as two directors retire

Tue, 25 Aug 2026 07:05:32 -0400

RegenxBio Inc. (Nasdaq: RGNX) appointed Greg Ciongoli to its board of directors, effective Aug. 25, 2026, according to a company statement. Concurrent with the appointment, two longtime independent directors — Jerry Karabelas, Ph.D., who served since 2015, and Jean Bennett, M.D., Ph.D., who served since 2021 — are retiring from the board.

Ciongoli is the founder and managing partner of Adiumentum Capital Management, an investment firm focused on capital structure optimization and asset allocation strategy. Before founding Adiumentum, he spent more than 16 years at The Baupost Group, where he served as partner of public group investing. He currently serves as

RegenxBio adds new board member as two directors retire

Tue, 25 Aug 2026 07:05:32 -0400

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Tue, 25 Aug 2026 07:05:00 -0400

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.

Concurrent with Mr. Ciongoli's appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Tue, 25 Aug 2026 07:05:00 -0400

Concurrent with Mr. Ciongoli's appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Tue, 25 Aug 2026 07:05:00 -0400

Concurrent with Mr. Ciongoli's appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Tue, 25 Aug 2026 07:05:00 -0400

Concurrent with Mr. Ciongoli's appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as

Regenxbio Inc. (RGNX) PT Lowered to $29 at Baird

Tue, 25 Aug 2026 06:18:46 -0400

Baird analyst Brian Skorney lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $29.00 (from $32.00) while maintaining a Outperform rating.

Form 8-K REGENXBIO Inc. For: Aug 24

Mon, 24 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26969170.html

Form 8-K REGENXBIO Inc. For: Aug 24

Mon, 24 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26969170.html

Regenxbio (RGNX) to Resume Trading at 7:25 am ET

Mon, 24 Aug 2026 07:13:21 -0400

Regenxbio (NASDAQ: RGNX) to Resume Trading at 7:25 am ET

FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome

Mon, 24 Aug 2026 07:05:32 -0400

Regenxbio Inc. (Nasdaq: RGNX) said the U.S. Food and Drug Administration has placed a clinical hold on its investigational gene therapy RGX-121 (clemidsogene lanparvovec) for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome, after asymptomatic spine MRI findings were discovered in five participants in the company's CAMPSIITE study.

The company said it does not expect to resubmit the RGX-121 Biologics License Application in the near term. Regenxbio and its partner NS Pharma said they will evaluate additional patient imaging and longer-term follow-up data, and will incorporate FDA feedback into next steps for the program.

The spine MRI findings — either

FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome

Mon, 24 Aug 2026 07:05:32 -0400

The spine MRI findings — either

FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome

Mon, 24 Aug 2026 07:05:32 -0400

The spine MRI findings — either

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Mon, 24 Aug 2026 07:05:00 -0400

ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE^® study; REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term.

"We believe these findings are unique and limited to our Hunter

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Mon, 24 Aug 2026 07:05:00 -0400

"We believe these findings are unique and limited to our Hunter

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Mon, 24 Aug 2026 07:05:00 -0400

"We believe these findings are unique and limited to our Hunter

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Mon, 24 Aug 2026 07:05:00 -0400

"We believe these findings are unique and limited to our Hunter